Tesamorelin + Ipamorelin Blend

Two-component GH-axis research pairing · no direct evidence for the exact combination

Component- and configuration-specific release; verify each identity, quantitative content, impurity profile, supplied form and, for co-formulated material, measured ratio on the batch documents · target, verify batch COACAS 218949-48-5RUO

Research statusComponent-level evidence only; no direct controlled evidence for the exact combined material was identified

Supplied formPeptide blend (two independently characterized components)

Lead timeConfirmed with quote

Tesamorelin + Ipamorelin Blend — Configuration and appearance are lot-specific. Confirm at quote stage whether Tesamorelin and Ipamorelin are supplied as separate characterized components or as a co-formulated material, then reconcile each component and the container on the released-lot documents.

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Component-level qualification avoids treating a blend name as a single identity claim.
Separate COA and identity evidence can support traceable experimental design.
The page explicitly distinguishes mechanistic rationale from direct combination evidence.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 218949-48-5
Formula: No unified formula — Tesamorelin reference free base: C₂₂₁H₃₆₆N₇₂O₆₇S; Ipamorelin reference free base: C₃₈H₄₉N₉O₅. Confirm salt, counterion and supplied-form basis for each component.
Molecular weight: Component-specific; no single molecular weight
Appearance: Configuration and appearance are lot-specific. Confirm at quote stage whether Tesamorelin and Ipamorelin are supplied as separate characterized components or as a co-formulated material, then reconcile each component and the container on the released-lot documents.
Purity: Component- and configuration-specific release; verify each identity, quantitative content, impurity profile, supplied form and, for co-formulated material, measured ratio on the batch documents · target, verify batch COA
Storage: Follow the released-lot COA and formulation-specific data for the exact shipping configuration. Separate-component stability does not establish co-formulated or reconstituted blend stability. For a pre-mixed material, require component recovery, ratio retention, adsorption, degradation, container compatibility and freeze–thaw data for the actual diluent, concentration, light, agitation, temperature and excursion conditions.
MOQ: On request
Lead time: Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Tesamorelin + Ipamorelin Blend

Tesamorelin and Ipamorelin are distinct peptides with separate identifiers, receptor pharmacology and evidence bases. This catalogue pairing is not a single chemical entity and has no unified CAS number, molecular formula, molecular weight or purity value. FDA approval applies to named EGRIFTA finished products with product-specific formulations and controls; it does not transfer to bulk Tesamorelin, Ipamorelin or this pairing. A targeted literature review identified component studies but no controlled study of the exact combined material.

Component-comparison research across GHRH-receptor and GHSR signaling
Protocol-defined dual-pathway experiments where both components are independently qualified

Mechanism context

The question the literature is testing

Tesamorelin is a growth-hormone-releasing hormone receptor agonist, whereas Ipamorelin is a growth-hormone secretagogue receptor 1a agonist. These pathways can converge on growth-hormone release, but receptor convergence does not establish additivity, synergy, timing, compatibility or a clinical effect for a specific ratio or co-formulation.

Evidence map

Research routes and exposure context

Evidence tierAnalytical / laboratory context

Research areaGrowth-hormone axis research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

A component's published safety or approved-product record does not validate the safety, compatibility or stability of the combination.
FDA lists Ipamorelin acetate among bulk substances that may present significant safety risks in compounding, citing aggregation, peptide-related impurities, immunogenicity concerns for certain routes and insufficient information for others.
This listing is for laboratory research use only and does not provide a human-use protocol.

Interactions reported in the literature

Direct compatibility, stability and interaction data for a co-formulated Tesamorelin + Ipamorelin material were not identified.
Any laboratory co-formulation requires protocol-specific assessment of ratio, solubility, adsorption, chromatographic interference and degradation; component compatibility cannot be assumed.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Tesamorelin + Ipamorelin Blend factory batch COAs

No factory batch COA is published for this product yet. Ask sales for the latest available document.

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Confirm the shipping configuration and each component's identity, supplied form, chromatographic purity, quantitative peptide content and relevant impurities independently.
For co-formulated material, also require target and measured ratio, homogeneity, mixture-capable assay, compatibility and stability data.
Sterility, endotoxin and other biological attributes are separate specifications and cannot be inferred from component HPLC area purity.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA and formulation-specific data for the exact shipping configuration. Separate-component stability does not establish co-formulated or reconstituted blend stability. For a pre-mixed material, require component recovery, ratio retention, adsorption, degradation, container compatibility and freeze–thaw data for the actual diluent, concentration, light, agitation, temperature and excursion conditions.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Current EGRIFTA WR prescribing information for product-specific Tesamorelin approval and formulation boundaries.
FDA's bulk-substances safety-risk page for current Ipamorelin acetate compounding context.
PubChem CID 16137828 and CID 9831659 for the separate Tesamorelin and Ipamorelin reference identities.
Falutz J et al. J Clin Endocrinol Metab. 2010. PMID 20554713; Gobburu JV et al. Pharm Res. 1999. PMID 10496658; and Raun K et al. Eur J Endocrinol. 1998. PMID 9849822, all as component-level evidence only.

01
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Journal of Clinical Endocrinology & Metabolism · 2010 · peer-reviewed original research (pooled multicentre randomized Phase 3 Tesamorelin trials and safety extensions; component-level clinical evidence)
Open source
02
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers
Pharmaceutical Research · 1999 · peer-reviewed original research (human intravenous Ipamorelin pharmacokinetic-pharmacodynamic study; component-level evidence)
Open source
03
Ipamorelin, the first selective growth hormone secretagogue
European Journal of Endocrinology · 1998 · peer-reviewed original research (preclinical cellular and animal pharmacology of Ipamorelin; component-level mechanistic evidence)
Open source
04
Ipamorelin — PubChem Compound Summary
PubChem, U.S. National Library of Medicine · 2026 · authoritative chemical database record
Open source
05
Tesamorelin — PubChem Compound Summary
PubChem, U.S. National Library of Medicine · 2026 · authoritative chemical database record
Open source
06
Ipamorelin acetate — compounding safety-risk information
U.S. Food and Drug Administration · 2026 · authoritative regulatory safety communication
Open source
07
EGRIFTA WR (tesamorelin) — full prescribing information
U.S. Food and Drug Administration / Drugs@FDA · 2025 · authoritative regulatory document (FDA-approved prescribing information)
Open source

Product FAQ

Questions buyers ask about Tesamorelin + Ipamorelin Blend

Does Tesamorelin evidence or EGRIFTA approval validate this Tesamorelin + Ipamorelin pairing?+

No. The current EGRIFTA WR label covers a named 11.6 mg Tesamorelin finished product with its own formulation, manufacturing controls, indication and instructions. Component trials similarly evaluate named materials and protocols. None establishes approval, safety, efficacy, compatibility, additivity or synergy for this exact pairing or for another ratio or co-formulation.

Is this supplied as two separate lots or as a pre-mixed material?+

The quote must state the configuration. Separate components require a COA and identity/content package for each lot. A co-formulated material additionally requires the target and measured component ratio, a mixture-capable identity and assay strategy, component-related impurities, homogeneity, compatibility and stability data. Do not infer the shipping format from the word blend.

Why is there no single CAS number, formula, molecular weight or purity value for the pairing?+

Tesamorelin and Ipamorelin are distinct molecules, so each retains its own registry identity, sequence, supplied form and analytical result. A mixture can report component-specific identity, content and impurity results plus a measured ratio, but it is not a new single molecular entity. A single HPLC area-purity number cannot establish both component contents or the blend ratio.

How should transport and storage be qualified for this two-component pairing?+

Use released-lot instructions and formulation-specific data for the exact shipping configuration. Separate-component stability does not prove stability after co-formulation. For a pre-mixed material, request component recovery and ratio retention under the proposed temperature, excursion, light, agitation and freeze–thaw conditions, together with adsorption, degradation and container-compatibility data for the actual concentration and diluent.

Tesamorelin + Ipamorelin Blend

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Tesamorelin + Ipamorelin Blend

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Tesamorelin + Ipamorelin Blend factory batch COAs

Ask for the current packet, not a generic certificate

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Ipamorelin, the first selective growth hormone secretagogue

Ipamorelin — PubChem Compound Summary

Tesamorelin — PubChem Compound Summary

Ipamorelin acetate — compounding safety-risk information

EGRIFTA WR (tesamorelin) — full prescribing information

Questions buyers ask about Tesamorelin + Ipamorelin Blend

Compare adjacent molecules and documentation needs.

Tesamorelin

Ipamorelin

CJC-1295 + Ipamorelin

Sermorelin